The global mycoplasma testing market is poised for substantial growth, with market value projected to increase from US$ 1.89 Bn in 2025 to US$ 4.52 Bn by 2032. The market is expected to register a robust CAGR of 11.5% from 2025 to 2032, driven by the increasing adoption of biologics, cell and gene therapies, and stringent quality control requirements across pharmaceutical and biotechnology industries.
Mycoplasma contamination remains one of the most significant challenges in cell culture-based manufacturing processes. These microorganisms can alter cell behavior, compromise research outcomes, and impact the safety and efficacy of biopharmaceutical products. As a result, manufacturers are increasingly implementing advanced mycoplasma testing protocols throughout research, development, and commercial production stages.
The rapid expansion of the biopharmaceutical sector is creating strong demand for reliable contamination detection solutions. Growing investments in monoclonal antibodies, vaccines, regenerative medicine, and cell-based therapies have intensified the need for comprehensive testing procedures to ensure product integrity. Regulatory agencies worldwide continue to emphasize rigorous testing standards, further supporting market growth.
For More Industry Insights Read: https://www.persistencemarketresearch.com/market-research/mycoplasma-testing-market.asp
PCR-Based Technologies Gain Momentum in Quality Assurance Programs
Polymerase Chain Reaction (PCR) technologies are emerging as a preferred testing approach due to their high sensitivity, rapid turnaround times, and ability to detect low levels of contamination. Compared to traditional microbial culture methods, PCR-based solutions enable faster decision-making and reduce delays in manufacturing workflows.
Biopharmaceutical companies are increasingly adopting molecular testing technologies to streamline quality control operations and accelerate product release timelines. The integration of automation and advanced analytical platforms is also improving testing efficiency, creating new opportunities for technology providers operating in the market.
Rising Cell and Gene Therapy Development Creates New Growth Opportunities
The growing pipeline of cell and gene therapies is expected to be a major growth catalyst for the mycoplasma testing market. These advanced therapies require highly controlled manufacturing environments where contamination risks must be minimized throughout the production process.
Cell banks, contract research organizations (CROs), and specialized therapy developers are increasingly investing in sophisticated testing solutions to meet regulatory expectations and maintain product quality. The expansion of personalized medicine and regenerative healthcare initiatives is expected to further strengthen demand for advanced contamination detection technologies.
North America Leads While Asia Pacific Emerges as a High-Growth Region
North America continues to maintain a dominant position in the global market, supported by a strong biotechnology ecosystem, extensive pharmaceutical manufacturing infrastructure, and strict regulatory compliance requirements. The presence of leading biopharmaceutical companies and ongoing investments in advanced therapeutics continue to support market expansion across the region.
Meanwhile, East Asia and South Asia & Oceania are emerging as attractive growth markets due to increasing pharmaceutical production activities, expanding contract manufacturing capabilities, and rising investments in biotechnology research. Governments across these regions are actively supporting life sciences innovation, creating favorable conditions for market growth.
Leading Companies Focus on Innovation and Strategic Expansion
Key market participants are investing in advanced testing technologies, automation capabilities, and service expansion strategies to strengthen their competitive position. Companies are also focusing on enhancing assay sensitivity, reducing testing times, and improving workflow integration to meet the evolving needs of biopharmaceutical manufacturers.
Companies Covered in the Mycoplasma Testing Market
- Thermo Fisher Scientific, Inc.
- Lonza Group AG
- Merck KGaA
- Charles River Laboratories International, Inc.
- PromoCell GmbH
- American Type Culture Collection
- Asahi Kasei Medical Co., Ltd
- Sartorius AG
- InvivoGen
- Eurofins Scientific
- ATCC (American Type Culture Collection)
Market Segmentation
By Technology
- PCR
- ELISA
- Direct Assay
- Microbial Culture
By End-user
- Biopharmaceutical
- CROs
- Cell Banks
By Product & Service
- Assays
- Kits
- Reagents
By Region
- North America
- Europe
- East Asia
- South Asia & Oceania
- Latin America
- Middle East & Africa
Explore the Latest Trending Research Reports:
- Sarcopenia Treatment Market: https://www.persistencemarketresearch.com/market-research/sarcopenia-treatment-market.asp
- Postural Orthostatic Tachycardia Syndrome (POTS) Treatment Market: https://www.persistencemarketresearch.com/market-research/postural-orthostatic-tachycardia-syndrome-treatment-market.asp
- Rodent Surgery Services Market: https://www.persistencemarketresearch.com/market-research/rodent-surgery-services-market.asp
- Glycan Analysis Market: https://www.persistencemarketresearch.com/market-research/glycan-analysis-market.asp